About Octant
Octant is a Healthcare company based in Los Angeles (United States) founded in 2017. Human cell interaction platform is provided for drug discovery. It operates on a HealthTech model. Octant has raised $110 million across 4 funding rounds from investors including HHS, Allen & Company and Bristol-Myers Squibb. The company has 63 employees. Octant offers products and services including OCT-980 and Genetic Disease Correctors. Its focus areas include Biotechnology and Precision Medicine. Its legal entity is OCTANT, INC. Its competitors include DNAnexus, Arbor Biotechnologies and Cytel; 3 of its 3 listed competitors have raised funding.
Company details
Octant is engaged in developing next-generation small molecule therapeutics by merging biology, chemistry, and computation. The company targets complex cellular mechanisms to address diseases caused by protein misfolding and mistrafficking. Solutions are built to deliver relief through innovative therapies, with a pipeline including treatments for retinitis pigmentosa, Fabry disease, and various cancers. Efforts are concentrated on precision medicine to transform drug discovery and clinical outcomes.
- Headquarters Los Angeles, United States
- Employees 63
- SectorsHealthcare
- Email••••••••
- Website octant.bio
- Social LinkedIn X
- Legal Name Octant, Inc.
- Total Equity Funding$110M (USD)
in 4 rounds
- Latest Funding Round$80M (USD), Series B
Apr 2022
- InvestorsHHS
& 7 more
- Employee Count63
Products & Services of Octant
Octant offers a comprehensive portfolio of products and services, including OCT-980 and Genetic Disease Correctors.
Designed to correct protein misfolding in retinal disorders.
Developed to address protein misfolding in genetic diseases.
Funding Insights of Octant
Octant has successfully raised a total of $110M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $80 million completed in April 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $110M
- Total Rounds 4
- Last Round Series B — $80M
- First Round $246,943
(May 2020)
- Investors Count 8
All 4 funding rounds of Octant with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2022 | $80M | Series B | – | Catalio Capital Management | |
| Apr 2021 | $316,638 | Grant | – | – | |
| May 2020 | $30M | Series A | – | a16z | |
| May 2020 | $246,943 | Grant | – | – |
8 investors in total: 8 institutional.
Investors in Octant
Octant has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, Allen & Company and Bristol-Myers Squibb.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital is provided to biomedical technology startups. | cataliocapital.com | New York, United States | ||
Venture capital investments in technology sectors are handled by Andreessen Horowitz. | a16z.com | |||
Venture capital firm focused on multiple sectors | fiftyyears.com | San Francisco, United States | ||
Venture capital firm investing in technology, life sciences, and related sectors. | 8vc.com | |||
Early-stage investments are provided to transformative technology companies. | svangel.com | San Francisco, United States | ||
Manufacturer of drugs for oncology, HIV/AIDS, cardiovascular disease, rheumatoid arthritis, and hepatitis | 1887 | bms.com | New York, United States | |
Wealth management firm | 1932 | alleninvestments.com | Lakeland, United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for Octant
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Octant
47 people are tracked at Octant (8 in leadership, 9 in board & advisors, 30 in team); the tracked headcount is 63.
| Name | Role | Group |
|---|---|---|
Eric M. Jones | Head Of Discovery Biology And Project Team Leader | Leadership |
Steven Edgar | Head Of Platform Analytical | Leadership |
Naomi Handly | VP Of Platform | Leadership |
Michelle Wong | Vice President Operations | Leadership |
Ramsey Homsany | Co-founder | Leadership |
Sri Kosuri | Co-founder And CEO | Leadership |
Joshua Paul | Head of Compute | Leadership |
Matthew Albert | VP, Discovery Biology & Early Clinical Development | Leadership |
Jorge Conde | Director | Board & advisors |
Mark Murcko | Director | Board & advisors |
George Petrocheilos | Director | Board & advisors |
Charles Zuker | Scientific Advisor | Board & advisors |
Debora Marks | Scientific Advisor | Board & advisors |
Jason Kelly | Director | Board & advisors |
Vijay Pande | Scientific Advisor | Board & advisors |
Hosea Nelson | Scientific Advisor | Board & advisors |
Rebecca Velez Frey | Director | Board & advisors |
Sathvik Koneru | Software Engineer | Team |
Yuning Shen | High Throughput Chemist, Drug Discovery Scientist | Team |
Marco Falcioni | Senior Software Engineer | Team |
27 more people are available in the full profile.
Complete people profiles for Octant
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Octant
3 dated milestones of Octant across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Octant is founded.
- Funding First funding round of $247K.
- Funding Latest funding round, Series B, of $80.0M.
Competitors of Octant
Octant has 3 listed competitors in our database, 3 of them funded. They include DNAnexus, Arbor Biotechnologies and Cytel.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| dnanexus.com | 2009 | Mountain View, United States | $472.55M | 143 | Cloud-based genome informatics and data management are provided. | |
| arbor.bio | 2016 | Cambridge, United States | $304.1M | 117 | Genomic technologies and drug discovery platforms are provided. | |
| cytel.com | 1987 | Cambridge, United States | $2M | 509 | Data analysis and statistical solutions are provided for life sciences. |
Detailed competitors of Octant
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Octant
The website of Octant (octant.bio) receives about 9.1K visits a month.
- Monthly visits9.1K
▼ 5.1% vs previous month
Websites whose visitors overlap most with Octant. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
kosurilab.org | kosurilab.org | 100% | #7,073,458 | – | |
deboramarkslab.com | deboramarkslab.com | 89% | #4,132,835 | – | |
| zetaschools.org | 57% | 36.3K | #849,222 | View details | |
| ionq.com | 47% | 321.8K | #190,698 | View details |
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Octant (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Octant
Complete news archive for Octant
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Octant
Octant was founded in 2017 and raised its 1st funding round 3 years after it was founded.
Octant is headquartered in Los Angeles, United States. It is registered at Los Angeles, California, United States.
Octant is a funded company, having raised a total of $110M across 4 funding rounds to date. The company's 1st funding round was a Grant of $246.94K, raised on May 2020.
Octant has 63 employees.
Octant is engaged in developing next-generation small molecule therapeutics by merging biology, chemistry, and computation. The company targets complex cellular mechanisms to address diseases caused by protein misfolding and mistrafficking. Solutions are built to deliver relief through innovative therapies, with a pipeline including treatments for retinitis pigmentosa, Fabry disease, and various cancers. Efforts are concentrated on precision medicine to transform drug discovery and clinical outcomes.
Octant's top competitors include DNAnexus, Arbor Biotechnologies and Cytel.
Octant offers OCT-980 and Genetic Disease Correctors.
Octant has 8 investors. Key investors include HHS, Allen & Company, Bristol-Myers Squibb, Catalio Capital Management, and Andreessen Horowitz.
Octant operates through Octant, Inc..